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Abstract
Regorafenib was shown to improve survival of patients with metastatic colorectal cancer resistant or unfit for
all available therapies. Data on the efficacy and safety of regorafenib in elderly patients are scarce. In this small
analysis, regorafenib administered with a modified schedule (2 weeks-on/1 week-off) to patients who were
aged ‡ 75 and non-frail with late-stage metastatic colorectal cancer appears to be tolerable and effective.
Background: In the CORRECT (patients with metastatic COloRectal Cancer treated with REgorafenib or plaCebo after
failure of standard Therapy) trial, regorafenib was proven to extend survival of patients with metastatic colorectal
cancer (mCRC) that progressed after all available therapies. Grade 3 to 4 toxicity occurred in 54% of patients, and data
on the activity and tolerability of regorafenib in elderly patients were scarce. The aim of this study was to evaluate the
efficacy and safety of an alternative schedule, 2-week-on treatment and 1 week-off (2/1 schedule), of regorafenib for
elderly patients with mCRC. Patients and Methods: Patients  75 years with mCRC who progressed after oxali-
platin- and irinotecan-based chemotherapy received regorafenib on a 2/1 schedule. Potentially frail subjects were
identified by G8 screening tool and excluded. The 2-month disease-control rate was the primary endpoint, and the
secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and objective response
rate. Results: Between February 2014 and May 2017, 23 patients with mCRC were recruited at our institution. No
partial or complete responses were observed, and the stable disease and disease-control rate were 52.2%. The
median PFS was 4.8 months (95% confidence interval, 3.8-6.3 months), and the median OS was 8.9 months (95%
confidence interval, 6.9-10.6 months). Adverse events were uncommon, and the most frequent grade 3 toxicity
adverse events were hand-foot skin reaction (9%) and fatigue (9%). Toxicity-related dose reductions and discon-
tinuations occurred in 5 and 2 patients, respectively. Conclusion: Regorafenib administered with a modified 2/1
schedule to patients who were aged  75 years and non-frail with treatment-refractory mCRC seems to be tolerable
and achieve encouraging results in terms of PFS and OS.
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Colorectal cancer (CRC) is one of the most frequent malignancies
worldwide. It is more common in the elderly (65 years), with
approximately 60%of diagnoses in patients aged 65 years or over.1 The
average life expectancy in the developed world is rapidly increasing and
so is the incidence of bowel cancer among elderly patients. However,
this category is still underrepresented in clinical trials, and data sup-
porting treatment for elderly patients with advanced CRC is scarce.2,3
The treatment of mCRC has drastically changed with the advent
of targeted therapies. These molecules include regorafenib, an oralClinical Colorectal Cancer Month 2018 - 1
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Regorafenib in Elderly Patientsmultikinase inhibitor that targets the multiple proangiogenic
signaling pathways inhibiting vascular endothelial growth factor
receptor (VEGF-R), fibroblast growth factor receptor (FGF-R), and
platelet-derived growth factor receptor (PDGF-R) and targets other
signaling oncogenic pathways such as KIT, RET, RAF-1, and
BRAF, and immunoglobulin and EGF tyrosine kinase.4,5 In the
CORRECT (patients with metastatic COloRectal Cancer treated
with REgorafenib or plaCebo after failure of standard Therapy)
randomized trial, regorafenib was shown to improve overall survival
(OS) of patients with mCRC previously treated with fluoropyr-
imidine-, oxaliplatin-, and irinotecan-based chemotherapy, or anti-
VEGF or, in KRAS wild-type, anti-epidermal growth factor recep-
tor (EGFR) targeted therapy compared with placebo (6.4 vs. 5.0
months; hazard ratio [HR], 0.77; 95% confidence interval [CI],
0.64-0.94; P ¼ .0052).6 Although the subgroup analysis reported
that patients  65 years achieved a survival benefit (HR, 0.86; 95%
CI, 0.61-1.19), the information for patients  75 years is limited
owing to their small number in this group (in the CORRECT trial,
only 38 patients  74 years received regorafenib).
Additionally, toxicity was notably more severe with regorafenib
than placebo, with grade 3 or 4 treatment-related adverse events
occurring in 54% (N ¼ 270) of the regorafenib-treated patients
versus 14% (N ¼ 35) of patients receiving placebo. Owing to the
adverse events, dose reductions were observed in 38% (N ¼ 188)
of patients, and therapy was interrupted in 61% (N ¼ 304) of
patients. Additionally, it should be noted that the median age of
the population was only 61 years, and adverse events data specific
to the elderly population were not reported.6 Therefore, evidence
supporting use of regorafenib in elderly patients is currently weak.
However, older adults with mCRC who failed the guidelines-
recommended chemotherapy regimens and still have a good
performance status (PS) and are considered fit on a comprehensive
geriatric assessment (CGA) are not rare and might benefit from an
active antitumoral treatment.7,8 In this regard, regorafenib could
be a viable option as last line of treatment if proven efficient
and safe.
The standard dosing schedule for regorafenib is 160 mg once
daily for 3 consecutive weeks followed by 1 week off (3/1 schedule),
and most of the severe side effects occurred during early phases of
exposure (after 1-2 cycles). To our knowledge, data in the literature
concerning alternative schedules for this drug or the safety and
efficacy of regorafenib in older adults are limited. With the aim to
improve the toxicity profile of regorafenib, a modified schedule
(2 weeks on treatment followed by 1 week off), entailing a shorter
exposure to the drug, was tested on a small cohort of elderly patients
at our institution. Based on the achieved promising preliminary
findings (unpublished data), the current study was designed to
evaluate the activity and safety of an alternative 2/1 schedule of
regorafenib in patients who were age  75 years with mCRC who
progressed after 2 or more previous chemotherapy lines.
Patients and Methods
Eligibility Criteria
Patients  75 years with documented mCRC who had pro-
gressed on previous oxaliplatin- and irinotecan-based chemotherapy
were enrolled at our institution in this prospective observational
study. The other eligibility criteria included age of 18 years ornical Colorectal Cancer Month 2018greater, Eastern Cooperative Oncology Group (ECOG) PS of 0 to
2, bidimensionally measurable disease, a life expectancy of at least
3 months, adequate hematologic parameters (an absolute neutrophil
count of  1.5  109/L and a platelet count of  100  109/L),
creatinine serum levels less than 1.5 times the upper limit of the
normal range, and total bilirubin levels less than 3-fold the upper
normal limit; aspartate and alanine aminotransferase less than 3-fold
the upper normal limit, and absence of a second primary tumor
other than non-melanoma skin cancer or in situ cervical carcinoma,
at baseline. Exclusion criteria were brain metastases or prior
treatment for brain metastasis; uncontrolled pleural or pericardial
effusion; clinically significant cardiovascular disease; and medically
uncontrolled hypertension.
At baseline, the G8 screening tool was used to identify potentially
frail subjects among the recruited patients9; subjects with  14
points were further evaluated by CGA.8 Patients classified as frail
were excluded from the study. The baseline geriatric assessment
included the Charlson Comorbidity Index and was performed by 2
medical oncologists (R.P. and L.M.) and a geriatrist (I.M.).10,11
Vulnerable patients were defined as subjects who resulted not in-
dependent in 1 or more activities according to the Instrumental
Activities of Daily Living and had 1 or 2 comorbidities with in-
termediate comorbidity score.
All patients gave their written informed consent prior to starting
treatment.
Patient Evaluation
A complete physical examination, monitoring of symptoms and
toxic effects, assessment of renal function, and a complete blood
count were performed on patients at day 1 of every cycle. In order to
minimize the risk of administering a potentially toxic drug to very
elderly patients without a clinical benefit, the disease was reassessed
after completion of 3 2/1-cycles of regorafenib (approximately after
8 weeks), then every 2 months for 6 months, and thereafter at
3-month intervals until there was evidence of disease progression.
Objective tumor response was evaluated radiologically according to
Response Evaluation Criteria in Solid Tumors (RECIST criteria,
version 1.1).
Treatment Delivery
Patients received regorafenib 160 mg once daily for 2 consecutive
weeks of each 3-week cycle (2/1 schedule). The starting dose was
reduced to 120 mg in patients considered vulnerable or with > 1
comorbidity and 80 mg in patients  80 years old or with an
ECOG PS of 2.
The dose was re-escalated to a maximum of 160 mg/day if no
grade  2 toxicity occurred.
Toxicity
The common toxicity criteria of the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE;
version 4.02) were used to assess toxicity. Treatment was delayed
if, on the planned treatment day, the neutrophil count was < 1500/
mm3, the platelet count was < 100,000/mm3, or the patient had
persistent diarrhea or stomatitis of grade 1 or higher. Any patient
who required more than 3 weeks for recovery from adverse reactions
was excluded from the study. In the event of grade 3 or greater
Table 1 Patient Characteristics
































Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status;
EGFR ¼ epidermal growth factor receptor; VEGF ¼ vascular endothelial growth factor.




Coronary artery disease 6 (26)
Arrhythmia 5 (22)




>1 comorbidities 17 (74)
Roberto Petrioli et alhematologic or any other severe (grade 3) organ toxicity, treat-
ment was delayed, and at recovery, regorafenib doses were reduced
by 40 mg (to a minimum of 80 mg) daily for subsequent courses.
Statistical Considerations
The primary endpoint of the study was 2-month disease-control
rate (DCR), defined as the percentage of patients who achieved
stable disease (SD) or partial (PR) or complete response (CR) within
2 months after start of therapy.
Regorafenib was recently approved by the United States Food
and Drug Administration and the European Medicine Agency as
salvage treatment for patients with mCRC who progressed after, or
are not considered fit for, available treatments including fluo-
ropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, or
anti-VEGF therapy or, if KRAS wild type, anti-EGFR targeted
therapy. The CORRECT study showed a 2-month DCR of
approximately 41% for patients treated with regorafenib. Given thatspecific data was not reported for elderly patients, and assuming a
0% to 5% 2-month DCR with best supportive care alone, the
hypothesis for the current study was that using a modified schedule
of regorafenib in patients  75 years, at least 25% of subjects would
be progression-free after 2 months from the start of treatment. It
was calculated that a total of 21 patients should be recruited to yield
a 80% probability to correctly select the treatment when it is
superior by absolute difference of 20% in 2-month DCR (Simon
minimax design).12
Secondary endpoints included safety, progression-free survival
(PFS), defined as time from treatment start to disease progression or
death from any cause, OS, as time elapsed from treatment initiation
to death from any cause, and objective response rate, as the pro-
portion of patients who achieved PR or CR. The Kaplan-Meier
method was used to determine PFS and OS. Statistical analyses
were conducted by STATA software.
Results
Patient Characteristics
Between February 2014 and May 2017, 23 patients > 75 years
of age with mCRC were enrolled in the study. The baseline char-
acteristics of patients are summarized in Table 1. The median age
was 78 years (range, 75-87 years), and 35% (N ¼ 8) of patients
were at least 80 years old. Most patients had an ECOG PS  1
(N ¼ 17; 73.9%) and were considered fit by CGA (N ¼ 18; 78%),
whereas 5 (22%) were classified as vulnerable. The median G8 score
of enrolled patients was 15 (range, 15-17) at baseline. The primary
tumor was located in the colon in 17 (74%) and the rectum in 6
(26%) patients. Eighteen subjects (78%) had liver metastases, and
17 (74%) had at least 1 metastatic site. All patients had at least 1
comorbidity, and the majority (N ¼ 17; 74%) had at least 2
(Table 2). The most frequent concomitant illnesses were cardio-
vascular diseases (48%).
Efficacy
All 23 patients received 1 or more cycles of regorafenib with
schedule 2/1 (median, 5 cycles; range, 2-14 cycles) and were
evaluable for response and toxicity. The starting dose is illustrated in
Table 3. The mean duration of treatment was 4.1 months (range,
1.1-11.7 months). The mean daily dose was 132.4 mg  24.7 mg
(median, 120 mg; range, 80-160 mg), and the planned dose rate
was 82.6%.Clinical Colorectal Cancer Month 2018 - 3
Table 3 Dose Modifications
N (%) Causes
Starting Dose
160 mg 8 (35) Fit, <80 y
120 mg 12 (52) Vulnerable, or >1 comorbidity
80 mg 3 (13) 80 y or ECOG PS ¼ 2
Escalated dose
From 120 mg to 160 mg 4 (17) After 1, 2, 2, 3 cycles, respectively
From 80 mg to 120 mg 3 (13) After 2, 2, 3 cycles, respectively
Reduced dose
From 160 mg to 120 mg 3 (13) After 1, 2, 4 cycles, respectively
From 160 mg to 80 mg 1 (4) After 1 cycle
From 120 mg to 80 mg 1 (4) After 3 cycles
Abbreviation: ECOG PS ¼ Eastern Cooperative Oncology Group performance status.








Fatigue 3 (13) 2 (9) 0
Hand-foot skin reaction 4 (17) 2 (9) 0
Figure 1 Kaplan-Meier Estimates of Overall Survival
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4 - CliNo patient achieved a CR or PR. Twelve patients (52.2%)
achieved SD, which was the best response to therapy (Table 4). In
this regard, computed tomography scans performed at 2 months
highlighted relevant tumor necrosis in the liver and/or in the
abdominal lymph nodes of 5 of the 12 patients with stable disease.
The 2-month DCR was 52.2% (95% CI, 31.6%-72.6%) (Table 4).
The median PFS was 4.8 months (95% CI, 3.8-6.3 months), and
the median OS was 8.9 months (95% CI, 6.9-10.6 months)
(Figure 1). At a median follow-up of 12.3 months (95% CI,
3.6-15.7 months), a total of 18 patients were deceased.
Regorafenib was discontinued owing to disease progression and
treatment-related adverse events in 91% and 9% of cases, respec-
tively. Four patients are still on treatment at data cut-off. Seven
patients who progressed after regorafenib received the following
anti-cancer treatments: oxaliplatin and capecitabine was adminis-
tered to 3 patients, capecitabine and cetuximab to 3 patients, and
capecitabine alone to 1 patient.
Treatment Toxicity
Adverse events rates are reported in Table 5. The most frequent
grade 3 side effects were fatigue, which occurred in 2 (9%) patients,
and hand-foot skin (HFS) reactions, which were reported in 2 (9%)
patients. Among grade 2 or lower adverse events, stomatitis, HFS,
and hypertransaminasemia were the most commonly observed. Five





Stable disease 12 (52)
Progressive disease 11 (48)
Two-month disease control rate, % (95% CI, %) 52.2 (31.6-72.6)
Progression-free survival, mos (95% CI, mos) 4.8 (3.8-6.3)
Overall survival, mos (95% CI, mos) 8.9 (6.9-10.6)
Abbreviation: CI ¼ Confidence interval.
nical Colorectal Cancer Month 2018occurred. Hematologic toxicity was mild. No patient required
hospitalization because of adverse events. Owing to toxicity, a dose
reduction was required in 5 (22%) patients, 4 of whom had started
with the conventional dose of 160 mg. Regorafenib was re-escalated
to 160 mg daily in 4 patients who had started with 120 mg. Two
(9%) patients interrupted the treatment: because of persistent HFS
after 4 cycles in 1 case and because of continuous HFS and fatigue
after 4 cycles in the other (Table 5).
Discussion
Despite the European Medicine Agency and United States Food
and Drug Administration approval of regorafenib as salvage treat-
ment for patients with mCRC who progressed after all available
therapies, the not neglectable toxicity profile of the conventional 3/1
schedule as well as the lack of efficacy and safety data on the elderly
population limit its use in clinical practice for the older adult.6 To
our knowledge, the present study is the first suggesting that anDiarrhea 3 (13) 1 (4) 0
Hypertension 3 (13) 1 (4) 0
Rash or desquamation 3 (13) 0 0
Nausea 2 (9) 0 0
Vomiting 1 (4) 0 0
Stomatitis 4 (17) 0 0
Constipation 3 (13) 1 (4) 0
Anorexia 2 (9) 1 (4) 0
Cardiac disorders 3 (13) 0 0
Hypertransaminasemia 4 (17) 1 (4) 0
Hyperbilirubinemia 2 (9) 0 0
Neutropenia 2 (9) 0 0
Anemia 3 (13) 0 0
Trombocytopenia 2 (9) 0 0
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patients aged  75 years and screened as non-frail with late-stage
mCRC. In fact, despite the limitations of a small observational
study, regorafenib seems at least as active in our population as in
that of the CORRECT trial. Similar to the latter, in our study there
was no CR, and PR and disease stabilization was the best response
to treatment, yet the 2-month DCR was 52.2%, the median PFS
was 4.8 months (95% CI, 3.8-6.3 months), and the median OS was
8.9 months (95% CI, 6.9-10.6 months) versus 41% (P < .0001),
1.9 months (95% CI, 1.6-3.9 months), and 6.4 months (95% CI,
3.6-11.8 months), respectively, in the CORRECT study.6
Furthermore, our findings compare well also with those described
by the international phase III trial CONCUR (asian subjects with
metastatic COlorectal caNCer treated with regorafenib or placebo
after failURe of standard therapy), which compared regorafenib
with best supportive care for Asian patients and reported a median
OS of 8.8 months (95% CI, 7.3-9.8 months) in the regorafenib-
treated group.13 A recent large retrospective Japanese study
assessed the efficacy of regorafenib versus the new agent trifluridine/
tipiracil (TFTD) for patients with mCRC who were refractory to
standard chemotherapy.14 The subgroup analysis by age reported a
median OS for the patients  65 years old treated with regorafenib
of 6.2 months (95% CI, 4.9-7.4 months), which is comparable to
that of the CORRECT trial and slightly shorter than that observed
in our analysis. The incidence of discontinuation because of
treatment-related toxicities was 24% in the regorafenib group versus
7% in the TFTD group, and the authors argued that regorafenib
tolerance, unlike TFTD, decreased in elderly patients compared
with younger patients. In a population aged 75 years or older (more
than one-third were at least 80 years of age), with at least 1 co-
morbidity (74% with 2), and who progressed after the standard
chemotherapy lines for mCRC, further treatment could be ques-
tioned as the toxicity can easily outweigh the potential benefit. For
this reason, this study used standard, validated tools of geriatric
assessment to guarantee that regorafenib would be delivered with a
personalized starting dose and only to non-frail patients. As a matter
of fact, at baseline, 78% of patients were considered fit by CGA
and, after a median follow-up of 12.3 months (95% CI, 3.6-15.7
months), 5 patients were still alive and 4 are still on treatment at
data cut-off. The use of a 2/1 schedule of administration allowed for
shortening the exposure to the drug, and this probably contributed
to the good tolerability of treatment with no unexpected severe side
effects. This is quite remarkable considering the advanced age of the
population, the amount of chemotherapy previously received, and
the presence of at least 1 concomitant disease. In particular, 48% of
our population presented with cardiac illnesses at baseline, and
recently, a large retrospective study comparing safety of targeted
therapies for mCRC between older and younger adults reported
more frequent cardiac disorders in the elderly patients treated with
bevacizumab, cetuximab, and regorafenib.15 In the current study,
cardiac disorders were mild, with only 1 case of grade 3 hyperten-
sion, and no heart failure occurred. In general, the observed toxicity
was milder than in the CORRECT trial. In this respect, except for a
similar incidence of grade 3 fatigue (9%), the rates of nearly all grade
3 adverse events were lower than in the pivotal trial. Consequently,
in the CORRECT study, the dose reductions and treatment in-
terruptions rates were considerably higher (38% and 61%,respectively) than in our analysis (22% and 9%, respectively).
Notably, 4 of the 5 patients who required a dose decrease in the
present study had started regorafenib at the standard dose, whereas
only 1 had a reduced starting dose of 120 mg. It should be noted
that the starting dose was, in most cases, lower than the standard
dose of 160 mg, and the 2/1 schedule allowed for a reduced
treatment exposure over time. However, the mean daily dose was
132.4 mg, and the planned dose rate was 82.6%, which compare
well with the mean daily dose of 147.1 mg and the dose intensity of
78.9% reported in the CORRECT trial.
Additionally, the reported safety profile was comparable to that of
the REBECCA (REgorafeniB in mEtastatic Colorectal cancer: a
french Compassionate progrAm) study, which analyzed in a real-life
setting, the efficacy and toxicity of regorafenib given to patients with
mCRC refractory to standard treatments.16 Interestingly, almost
one-half (47.6%) of the 1178 patients enrolled in this study were
elderly. However, the side effects required treatment interruptions
and dose reductions in 31% and 43% of patients, respectively, and
thus were not as easily manageable as in our study.16 This is
probably the result of a combination of factors in our analysis,
including the shorter exposure to regorafenib allowed by the
modified 2/1 schedule, the accurate selection of non-frail subjects,
and the starting dose reductions for the patients who were non-fit or
aged  80 years. In this regard, as far as we are aware, no data
surrounding the use of a modified schedule of regorafenib for
mCRC have been previously reported. However, similar experiences
have been documented with the multikinase inhibitor sunitinib for
the treatment of metastatic renal cell cancer to improve its safety
profile. A small study showed a better toxicity profile for sunitinib in
a 2-weeks-on/1-week-off regimen compared with the conventional
4/2 schedule, while maintaining the standard dose intensity.17
Moreover, a large retrospective analysis reported a better tolera-
bility and no decrease in efficacy for the patients with metastatic
renal cell cancer who switched from the standard 4/2 to the
modified 2/1 schedule of sunitinib owing to adverse events.18
Despite the encouraging results of our analysis, the small size of
the population is a limitation that prevents us from drawing general
conclusions. Larger randomized trials of comparison between the
conventional 3/1 and the alternative 2/1 schedule of administration
should be performed in order to confirm our safety and efficacy
results. However, these data showed that regorafenib given with a
modified 2/1 schedule as last-line treatment for non-frail, 75 years
or older patients with mCRC who are refractory to standard
chemotherapy is well-tolerated and efficient. Finally, this altered
schedule may also be relevant for patients younger than 75 years as
the on-label dose and schedule of 160 mg for 3 weeks on, 1 week off
is not well-tolerated. Further studies will be required to verify
whether the modified 120 mg 2/1 dose and schedule might be a
more tolerated and equally effective regimen for all patients,
regardless of age.
Conclusion
Although careful monitoring of potential side effects is still
recommended, this analysis suggests that regorafenib given with
a modified 2/1 schedule may be safely proposed for selected
elderly patients with mCRC who failed previous standard
chemotherapy.Clinical Colorectal Cancer Month 2018 - 5
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 In the CORRECT randomized trial, regorafenib was shown to
prolong survival of patients with treatment-refractory mCRC.
However, there is little data in the literature over the tolerability and
efficacy of regorafenib in elderly patients or when administered with
a different schedule. Additionally, regorafenib-related adverse events
were not neglectable and mostly occurred during cycle 1 to 2.
 In this prospective study, 23 patients with mCRC who were 
75 years old, had progressed after the standard lines of chemo-
therapy, and were screened as non-frail received regorafenib with
a modified schedule consisting of 2 weeks on treatment and 1
week off. More than one-half (52.2%) of the patients obtained
disease stabilization, and both median OS and PFS compared
well with those observed in the CORRECT study. Adverse
events, in particular grade 3, were uncommon and led to only 5
dose modifications and 2 treatment discontinuations.
 A modified 2/1 schedule of regorafenib combined with an
initially personalized starting dose might be safely proposed for
selected elderly patients  75 years with mCRC.Disclosure
The authors have stated that they have no conflicts of interest.
Supplemental Data
Supplemental data accompanying this article can be found in the
online version at https://doi.org/10.1016/j.clcc.2018.02.005.References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;
63:11-30.
2. Aparicio T, Pamoukdjian F, Quero L, et al. Colorectal cancer care in elderly pa-
tients: unsolved issues. Dig Liver Dis 2016; 48:1112-8.
3. Gouverneur A, Salvo F, Berdaï D, et al. Inclusion of elderly or frail patients in
randomized controlled trials of targeted therapies for the treatment of metastatic
colorectal cancer: a systematic review. J Geriatr Oncol 2018; 9:15-23.nical Colorectal Cancer Month 20184. Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): anti-
tumor and antimetastatic activities in preclinical models of colorectal cancer. Int J
Cancer 2014; 135:1487-96.
5. Sartore-Bianchi A, Zeppellini A, Amatu A, Ricotta R, Bencardino K, Siena S. Regor-
afenib in metastatic colorectal cancer. Expert Rev Anticancer Ther 2014; 14:255-65.
6. Grothey A, Van Cutsem E, Sobrero A, et al, CORRECT Study Group. Regor-
afenib monotherapy for previously treated metastatic colorectal cancer (COR-
RECT): an international, multicentre, randomised, placebo-controlled, phase 3
trial. Lancet 2013; 381:303-12.
7. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for
management of patients with colon and rectal cancer. A personalized approach to
clinical decision making. Ann Oncol 2012; 23:2479-516.
8. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology
consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;
32:2595-603.
9. Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer
patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One
2014; 9:e115060.
10. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds
information to Eastern Cooperative Oncology Group performance status in elderly
cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;
20:494-502.
11. Balducci L, Extermann M. Management of cancer in the older person: a practical
approach. Oncologist 2000; 5:224-37.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials
1989; 10:1-10.
13. Li J, Qin S, Xu R, et al, CONCUR Investigators. Regorafenib plus best supportive
care versus placebo plus best supportive care in Asian patients with previously
treated metastatic colorectal cancer (CONCUR): a randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16:619-29.
14. Moriwaki T, Fukuoka S, Taniguchi H, et al. Propensity score analysis of
regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal
cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for
Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist
2018; 23:7-15.
15. Gouverneur A, Claraz P, Rousset M, et al. Comparative safety of targeted
therapies for metastatic colorectal cancer between elderly and younger patients:
a study using the International Pharmacovigilance Database. Target Oncol 2017;
12:805-14.
16. Adenis A, de la Fouchardiere C, Paule B, et al. Survival, safety, and prognostic
factors for outcome with regorafenib in patients with metastatic colorectal
cancer refractory to standard therapies: results from a multicenter study
(REBACCA) nested within a compassionate use program. BMC Cancer 2016;
16:412.
17. Makino K, Yoda K, Tomoishi J, Kume H. Efficacy and tolerability of a low-dose,
2-week administration of sunitinib followed by a week rest (2/1 schedule) for
metastatic renal cell carcinoma: a single center experience of six cases. BMC Res
Notes 2014; 7:872.
18. Bracarda S, Iacovelli R, Boni L, et al, Rainbow Group. Sunitinib administered on
2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW
analysis. Ann Oncol 2016; 27:366.
